Humalog Mix 25 Kwikpen 100IU/ml is a premixed insulin formulation containing 25% insulin lispro and 75% insulin lispro protamine suspension, designed for the management of diabetes mellitus requiring insulin therapy. Insulin lispro is a rapid-acting insulin analogue that facilitates prompt postprandial glucose control by mimicking physiological insulin secretion, while insulin lispro protamine acts as an intermediate-acting component, providing prolonged basal insulin coverage. This combination allows for both immediate and sustained glycemic regulation, reducing the frequency of injections compared to separate basal and bolus insulins. Humalog Mix 25 Kwikpen is administered subcutaneously and is indicated for adult and pediatric patients with type 1 diabetes mellitus and for adults with type 2 diabetes mellitus when oral agents are insufficient. The Kwikpen device offers a convenient, prefilled, and disposable delivery system, enhancing dosing accuracy and patient compliance. Dosage must be individualized based on metabolic needs, blood glucose monitoring, and glycemic control goals. Caution is advised to avoid hypoglycemia, and patients should be educated on recognizing and managing low blood sugar episodes. Proper injection technique and rotation of injection sites are essential to minimize lipodystrophy. Humalog Mix 25 Kwikpen should be stored according to manufacturer guidelines to maintain insulin potency.